CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops

• Status: Recruiting
• Trial end date: 2022-12-15
• Target enrollment: 0
• Participant gender: All

Summary

CHED- Congenital Endothelial Endothelial Dystrophy is a condition that causes corneal cloudiness.

Since, currently only surgery is being done to cure this condition, we are taking up the research of using topical eye drops for this condition which is a very simple and easy method.

Also, there are no significant side effects to this treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: L.V. Prasad Eye Institute
• Collaborator: Allergan
• Treatments: Carboxymethylcellulose Sodium; Lubricant Eye Drops; Nepafenac; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Children upto 9 years of age diagnosed with CHED (Congenital Hereditary Endothelial Dystrophy) with bilaterally equal corneal involvement

• Patients agreeing on a regular monthly follow-up for a minimum of 6 months

Exclusion Criteria:

• Patient undergone any other surgery like Penetrating keratoplasty (PK), Descemet stripping automated endothelial keratoplasty (DSEK) and Descemet's membrane endothelial keratoplasty (DMEK), Glaucoma surgeries, in one of both eyes

• Patients with concomitant ophthalmic pathologies like glaucoma, poor corneal surface, dry eye disease, corneal ulcers, systemic inflammatory conditions, cataract, nystagmus, Reduced corneal sensation etc.

• Patients not able to come for follow-ups

• Asymmetrical corneal involvement

• Patients with known allergy to ophthalmic NSAID's

• Patients with asthma or bleeding dyscrasias

• Non-cooperative children